FDA Expands Approval of Agilent's Diagnostic Test for Keytruda Patients
The U.S. FDA has expanded the indication for Agilent Technologies' PD-L1 IHC 22C3 pharmDx test to support decision-making in patients with four additional tumor types who may benefit from Merck’s Keytruda treatment.
